216 related articles for article (PubMed ID: 30622456)
21. Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents.
Polinski NK; Volpicelli-Daley LA; Sortwell CE; Luk KC; Cremades N; Gottler LM; Froula J; Duffy MF; Lee VMY; Martinez TN; Dave KD
J Parkinsons Dis; 2018; 8(2):303-322. PubMed ID: 29400668
[TBL] [Abstract][Full Text] [Related]
22. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.
Myöhänen TT; Norrbacka S; Savolainen MH
Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354
[TBL] [Abstract][Full Text] [Related]
23. Inducible Alpha-Synuclein Expression Affects Human Neural Stem Cells' Behavior.
Zasso J; Ahmed M; Cutarelli A; Conti L
Stem Cells Dev; 2018 Jul; 27(14):985-994. PubMed ID: 29669468
[TBL] [Abstract][Full Text] [Related]
24. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF
Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414
[TBL] [Abstract][Full Text] [Related]
25. The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro.
Dulovic M; Jovanovic M; Xilouri M; Stefanis L; Harhaji-Trajkovic L; Kravic-Stevovic T; Paunovic V; Ardah MT; El-Agnaf OM; Kostic V; Markovic I; Trajkovic V
Neurobiol Dis; 2014 Mar; 63():1-11. PubMed ID: 24269733
[TBL] [Abstract][Full Text] [Related]
26. Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains.
Piltonen M; Savolainen M; Patrikainen S; Baekelandt V; Myöhänen TT; Männistö PT
Neuroscience; 2013 Feb; 231():157-68. PubMed ID: 23219665
[TBL] [Abstract][Full Text] [Related]
27. Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease.
Zella MAS; Metzdorf J; Ostendorf F; Maass F; Muhlack S; Gold R; Haghikia A; Tönges L
Cells; 2019 Jan; 8(2):. PubMed ID: 30708997
[TBL] [Abstract][Full Text] [Related]
28. Does retina play a role in Parkinson's Disease?
Mohana Devi S; Mahalaxmi I; Aswathy NP; Dhivya V; Balachandar V
Acta Neurol Belg; 2020 Apr; 120(2):257-265. PubMed ID: 31965540
[TBL] [Abstract][Full Text] [Related]
29. Membrane binding, internalization, and sorting of alpha-synuclein in the cell.
Masaracchia C; Hnida M; Gerhardt E; Lopes da Fonseca T; Villar-Pique A; Branco T; Stahlberg MA; Dean C; Fernández CO; Milosevic I; Outeiro TF
Acta Neuropathol Commun; 2018 Aug; 6(1):79. PubMed ID: 30107856
[TBL] [Abstract][Full Text] [Related]
30. Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.
Musacchio T; Rebenstorff M; Fluri F; Brotchie JM; Volkmann J; Koprich JB; Ip CW
Ann Neurol; 2017 Jun; 81(6):825-836. PubMed ID: 28470693
[TBL] [Abstract][Full Text] [Related]
31. Glycation modulates glutamatergic signaling and exacerbates Parkinson's disease-like phenotypes.
Chegão A; Guarda M; Alexandre BM; Shvachiy L; Temido-Ferreira M; Marques-Morgado I; Fernandes Gomes B; Matthiesen R; Lopes LV; Florindo PR; Gomes RA; Gomes-Alves P; Coelho JE; Outeiro TF; Vicente Miranda H
NPJ Parkinsons Dis; 2022 Apr; 8(1):51. PubMed ID: 35468899
[TBL] [Abstract][Full Text] [Related]
32. Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification.
Fenyi A; Leclair-Visonneau L; Clairembault T; Coron E; Neunlist M; Melki R; Derkinderen P; Bousset L
Neurobiol Dis; 2019 Sep; 129():38-43. PubMed ID: 31078683
[TBL] [Abstract][Full Text] [Related]
33. Polymer brain-nanotherapeutics for multipronged inhibition of microglial α-synuclein aggregation, activation, and neurotoxicity.
Bennett NK; Chmielowski R; Abdelhamid DS; Faig JJ; Francis N; Baum J; Pang ZP; Uhrich KE; Moghe PV
Biomaterials; 2016 Dec; 111():179-189. PubMed ID: 27736702
[TBL] [Abstract][Full Text] [Related]
34. Modulation of alpha-synuclein toxicity in yeast using a novel microfluidic-based gradient generator.
Fernandes JT; Tenreiro S; Gameiro A; Chu V; Outeiro TF; Conde JP
Lab Chip; 2014 Oct; 14(20):3949-57. PubMed ID: 25167219
[TBL] [Abstract][Full Text] [Related]
35. Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease.
Magen I; Torres ER; Dinh D; Chung A; Masliah E; Chesselet MF
J Parkinsons Dis; 2015; 5(3):669-680. PubMed ID: 25588356
[TBL] [Abstract][Full Text] [Related]
36. Formation of large oligomers of DOPAL-modified α-synuclein is modulated by the oxidation of methionine residues located at C-terminal domain.
Coelho-Cerqueira E; de Araújo Correia Campos C; Follmer C
Biochem Biophys Res Commun; 2019 Feb; 509(2):367-372. PubMed ID: 30591215
[TBL] [Abstract][Full Text] [Related]
37. Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities.
Visanji NP; Lang AE; Kovacs GG
Transl Neurodegener; 2019; 8():28. PubMed ID: 31508228
[TBL] [Abstract][Full Text] [Related]
38. Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies.
Magalhães P; Lashuel HA
NPJ Parkinsons Dis; 2022 Jul; 8(1):93. PubMed ID: 35869066
[TBL] [Abstract][Full Text] [Related]
39. Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils.
Zhang B; Kehm V; Gathagan R; Leight SN; Trojanowski JQ; Lee VM; Luk KC
Methods Mol Biol; 2019; 1948():45-57. PubMed ID: 30771169
[TBL] [Abstract][Full Text] [Related]
40. Kir6.1/K-ATP channel on astrocytes protects against dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease via promoting mitophagy.
Hu ZL; Sun T; Lu M; Ding JH; Du RH; Hu G
Brain Behav Immun; 2019 Oct; 81():509-522. PubMed ID: 31288070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
